Market Access The benefits of ePI for patients and the planet With one change made by one pharmaceutical company, we could save half a million trees every year. Imagine the impact if the change was made across industry.
Market Access Exploring the potential of FHIRs and e-labelling Fast Healthcare Interoperability Resources (FHIRs) allow fast to bu
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.